Summit Therapeutics Inc.
SMMTNASDAQHealthcare● Active
$14.41
$-0.36(-2.42%)
Market Cap$11.2B
P/E Ratio—
52W High$30.98
52W Low$13.83
Summit Therapeutics Inc. (SMMT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SMMT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.54B | $0.13B | $0.46B | $0.04B | $0.06B |
| G&A Expenses | $0.56B | $0.05B | $0.02B | $0.02B | $0.02B |
| Total Operating Expenses | $1.09B | $0.18B | $0.48B | $0.06B | $0.07B |
| Operating Income | ($1.09B) | ($0.18B) | ($0.48B) | ($0.06B) | ($0.06B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.01B | $0.02B | $0.00B | $0.00B |
| Income Before Tax | ($1.08B) | ($0.18B) | ($0.48B) | ($0.07B) | ($0.07B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($1.08B) | ($0.18B) | ($0.48B) | ($0.07B) | ($0.07B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.44 | $-0.25 | $-0.78 | $-0.34 | $-0.71 |
| Wtd Avg Shares | 0.75B | 0.71B | 0.62B | 0.19B | 0.09B |
| EBITDA | ($1.08B) | ($0.17B) | ($0.07B) | ($0.05B) | ($0.06B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Summit Therapeutics Inc. data
About Summit Therapeutics Inc. (SMMT) Income Statement
Summit Therapeutics Inc. (SMMT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SMMT reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($1.08B) — a net profit margin of —.
Frequently asked questions
SMMT · 4 questionsSummit Therapeutics Inc. (SMMT) reported revenue of $0.00B for 2025, down —% year-over-year.
SMMT revenueSMMT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08